Developing a claim-based version of the ACE-27 comorbidity index

A comparison with medical record review

Steven T. Fleming, Susan A. Sabatino, Gretchen Kimmick, Rosemary Cress, Xiao Cheng Wu, Amy Trentham-Dietz, Bin Huang, Wenke Hwang, Jonathan Liff

Research output: Contribution to journalReview article

22 Citations (Scopus)

Abstract

ObjectiveS: The adult comorbidity evaluation (ACE-27) is a medical record-based comorbidity index that predicts survival among various types of cancer patients. The purpose of this study was to compare the medical record-based ACE-27 instrument to a newly developed administrative claim-based ACE-27 measure. Study Design and Setting: Cross-sectional study of 4,300 breast and prostate cancer patients from the Centers for Disease Control and Prevention Patterns of Care Study. Results: Comorbidities with the highest concordance were diabetes (sensitivity=84.6%, κ=0.58 for breast cancer patients; sensitivity=0.764, κ=0.54 for prostate cancer patients), and hypertension (sensitivity=78.5%, κ=0.32 for breast cancer patients; sensitivity=69.6%, κ=0.28 for prostate cancer patients). Diseases with fair or moderate agreement in one or both cancer sites include congestive heart failure, arrhythmia, hypertension, respiratory diseases, hepatic disease, renal disease, dementia, and neuromuscular disease. For overall indices, agreement was fair but with high sensitivities in the collapsed indices, and the highest sensitivities in the lowest level of decompensation. Conclusions: The ACE-27 comorbidity score derived from administrative claims data provides a tool to examine the relationship between comorbidity, cancer diagnosis, and outcomes in future epidemiologic research, particularly when medical record review is logistically impossible. The classification of most comorbidities into 2 or 3 levels of severity within a claim-based measure is a major development. Future research should be directed toward refining the measure with a longer review period or different paradigms for diagnosis identification, and testing the predictive ability of the measure in terms of survival, complications, or other outcomes of care.

Original languageEnglish (US)
Pages (from-to)752-760
Number of pages9
JournalMedical Care
Volume49
Issue number8
DOIs
StatePublished - Aug 1 2011

Fingerprint

Medical Records
Comorbidity
Prostatic Neoplasms
Breast Neoplasms
Hypertension
Neoplasms
Neuromuscular Diseases
Aptitude
Survival
Centers for Disease Control and Prevention (U.S.)
Dementia
Cardiac Arrhythmias
Heart Failure
Cross-Sectional Studies
Kidney
Liver
Research

All Science Journal Classification (ASJC) codes

  • Public Health, Environmental and Occupational Health

Cite this

Fleming, S. T., Sabatino, S. A., Kimmick, G., Cress, R., Wu, X. C., Trentham-Dietz, A., ... Liff, J. (2011). Developing a claim-based version of the ACE-27 comorbidity index: A comparison with medical record review. Medical Care, 49(8), 752-760. https://doi.org/10.1097/MLR.0b013e318215d7dd
Fleming, Steven T. ; Sabatino, Susan A. ; Kimmick, Gretchen ; Cress, Rosemary ; Wu, Xiao Cheng ; Trentham-Dietz, Amy ; Huang, Bin ; Hwang, Wenke ; Liff, Jonathan. / Developing a claim-based version of the ACE-27 comorbidity index : A comparison with medical record review. In: Medical Care. 2011 ; Vol. 49, No. 8. pp. 752-760.
@article{2f90fbc3045b4c8483b7baf44986c01d,
title = "Developing a claim-based version of the ACE-27 comorbidity index: A comparison with medical record review",
abstract = "ObjectiveS: The adult comorbidity evaluation (ACE-27) is a medical record-based comorbidity index that predicts survival among various types of cancer patients. The purpose of this study was to compare the medical record-based ACE-27 instrument to a newly developed administrative claim-based ACE-27 measure. Study Design and Setting: Cross-sectional study of 4,300 breast and prostate cancer patients from the Centers for Disease Control and Prevention Patterns of Care Study. Results: Comorbidities with the highest concordance were diabetes (sensitivity=84.6{\%}, κ=0.58 for breast cancer patients; sensitivity=0.764, κ=0.54 for prostate cancer patients), and hypertension (sensitivity=78.5{\%}, κ=0.32 for breast cancer patients; sensitivity=69.6{\%}, κ=0.28 for prostate cancer patients). Diseases with fair or moderate agreement in one or both cancer sites include congestive heart failure, arrhythmia, hypertension, respiratory diseases, hepatic disease, renal disease, dementia, and neuromuscular disease. For overall indices, agreement was fair but with high sensitivities in the collapsed indices, and the highest sensitivities in the lowest level of decompensation. Conclusions: The ACE-27 comorbidity score derived from administrative claims data provides a tool to examine the relationship between comorbidity, cancer diagnosis, and outcomes in future epidemiologic research, particularly when medical record review is logistically impossible. The classification of most comorbidities into 2 or 3 levels of severity within a claim-based measure is a major development. Future research should be directed toward refining the measure with a longer review period or different paradigms for diagnosis identification, and testing the predictive ability of the measure in terms of survival, complications, or other outcomes of care.",
author = "Fleming, {Steven T.} and Sabatino, {Susan A.} and Gretchen Kimmick and Rosemary Cress and Wu, {Xiao Cheng} and Amy Trentham-Dietz and Bin Huang and Wenke Hwang and Jonathan Liff",
year = "2011",
month = "8",
day = "1",
doi = "10.1097/MLR.0b013e318215d7dd",
language = "English (US)",
volume = "49",
pages = "752--760",
journal = "Medical Care",
issn = "0025-7079",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

Fleming, ST, Sabatino, SA, Kimmick, G, Cress, R, Wu, XC, Trentham-Dietz, A, Huang, B, Hwang, W & Liff, J 2011, 'Developing a claim-based version of the ACE-27 comorbidity index: A comparison with medical record review', Medical Care, vol. 49, no. 8, pp. 752-760. https://doi.org/10.1097/MLR.0b013e318215d7dd

Developing a claim-based version of the ACE-27 comorbidity index : A comparison with medical record review. / Fleming, Steven T.; Sabatino, Susan A.; Kimmick, Gretchen; Cress, Rosemary; Wu, Xiao Cheng; Trentham-Dietz, Amy; Huang, Bin; Hwang, Wenke; Liff, Jonathan.

In: Medical Care, Vol. 49, No. 8, 01.08.2011, p. 752-760.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Developing a claim-based version of the ACE-27 comorbidity index

T2 - A comparison with medical record review

AU - Fleming, Steven T.

AU - Sabatino, Susan A.

AU - Kimmick, Gretchen

AU - Cress, Rosemary

AU - Wu, Xiao Cheng

AU - Trentham-Dietz, Amy

AU - Huang, Bin

AU - Hwang, Wenke

AU - Liff, Jonathan

PY - 2011/8/1

Y1 - 2011/8/1

N2 - ObjectiveS: The adult comorbidity evaluation (ACE-27) is a medical record-based comorbidity index that predicts survival among various types of cancer patients. The purpose of this study was to compare the medical record-based ACE-27 instrument to a newly developed administrative claim-based ACE-27 measure. Study Design and Setting: Cross-sectional study of 4,300 breast and prostate cancer patients from the Centers for Disease Control and Prevention Patterns of Care Study. Results: Comorbidities with the highest concordance were diabetes (sensitivity=84.6%, κ=0.58 for breast cancer patients; sensitivity=0.764, κ=0.54 for prostate cancer patients), and hypertension (sensitivity=78.5%, κ=0.32 for breast cancer patients; sensitivity=69.6%, κ=0.28 for prostate cancer patients). Diseases with fair or moderate agreement in one or both cancer sites include congestive heart failure, arrhythmia, hypertension, respiratory diseases, hepatic disease, renal disease, dementia, and neuromuscular disease. For overall indices, agreement was fair but with high sensitivities in the collapsed indices, and the highest sensitivities in the lowest level of decompensation. Conclusions: The ACE-27 comorbidity score derived from administrative claims data provides a tool to examine the relationship between comorbidity, cancer diagnosis, and outcomes in future epidemiologic research, particularly when medical record review is logistically impossible. The classification of most comorbidities into 2 or 3 levels of severity within a claim-based measure is a major development. Future research should be directed toward refining the measure with a longer review period or different paradigms for diagnosis identification, and testing the predictive ability of the measure in terms of survival, complications, or other outcomes of care.

AB - ObjectiveS: The adult comorbidity evaluation (ACE-27) is a medical record-based comorbidity index that predicts survival among various types of cancer patients. The purpose of this study was to compare the medical record-based ACE-27 instrument to a newly developed administrative claim-based ACE-27 measure. Study Design and Setting: Cross-sectional study of 4,300 breast and prostate cancer patients from the Centers for Disease Control and Prevention Patterns of Care Study. Results: Comorbidities with the highest concordance were diabetes (sensitivity=84.6%, κ=0.58 for breast cancer patients; sensitivity=0.764, κ=0.54 for prostate cancer patients), and hypertension (sensitivity=78.5%, κ=0.32 for breast cancer patients; sensitivity=69.6%, κ=0.28 for prostate cancer patients). Diseases with fair or moderate agreement in one or both cancer sites include congestive heart failure, arrhythmia, hypertension, respiratory diseases, hepatic disease, renal disease, dementia, and neuromuscular disease. For overall indices, agreement was fair but with high sensitivities in the collapsed indices, and the highest sensitivities in the lowest level of decompensation. Conclusions: The ACE-27 comorbidity score derived from administrative claims data provides a tool to examine the relationship between comorbidity, cancer diagnosis, and outcomes in future epidemiologic research, particularly when medical record review is logistically impossible. The classification of most comorbidities into 2 or 3 levels of severity within a claim-based measure is a major development. Future research should be directed toward refining the measure with a longer review period or different paradigms for diagnosis identification, and testing the predictive ability of the measure in terms of survival, complications, or other outcomes of care.

UR - http://www.scopus.com/inward/record.url?scp=79961021810&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79961021810&partnerID=8YFLogxK

U2 - 10.1097/MLR.0b013e318215d7dd

DO - 10.1097/MLR.0b013e318215d7dd

M3 - Review article

VL - 49

SP - 752

EP - 760

JO - Medical Care

JF - Medical Care

SN - 0025-7079

IS - 8

ER -